United States Bi-Specific Antibodies Therapy Market Report & Forecast 2021-2027
Table of Contents1 Introduction to Research & Analysis Reports
1.1 Bi-Specific Antibodies Therapy Market Definition
1.2 Market Segments
1.2.1 Segment by Type
1.2.2 Segment by Application
1.3 United States Bi-Specific Antibodies Therapy Market Overview
1.4 Methodology & Sources of Information
1.4.1 Research Methodology
1.4.2 Research Process
1.4.3 Base Year
2 United States Bi-Specific Antibodies Therapy Overall Market Size
2.1 United States Bi-Specific Antibodies Therapy Market Size: 2021 VS 2027
2.2 United States Bi-Specific Antibodies Therapy Revenue, Prospects & Forecasts: 2016-2027
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Bi-Specific Antibodies Therapy Players in United States Market
3.2 Top United States Bi-Specific Antibodies Therapy Companies Ranked by Revenue
3.3 United States Bi-Specific Antibodies Therapy Revenue by Companies
3.4 Top 3 and Top 5 Bi-Specific Antibodies Therapy Companies in United States Market, by Revenue in 2020
3.5 Companies Bi-Specific Antibodies Therapy Product Type
3.6 Tier 1, Tier 2 and Tier 3 Bi-Specific Antibodies Therapy Players in United States Market
3.6.1 List of Tier 1 Bi-Specific Antibodies Therapy Companies in United States
3.6.2 List of Tier 2 and Tier 3 Bi-Specific Antibodies Therapy Companies in United States
4 Sights by Type
4.1 Overview
4.1.1 By Type - United States Bi-Specific Antibodies Therapy Market Size Markets, 2021 & 2027
4.1.2 Fragment-Based Antibodies
4.1.3 IgG-Based Antibodies
4.2 By Type - United States Bi-Specific Antibodies Therapy Revenue & Forecasts
4.2.1 By Type - United States Bi-Specific Antibodies Therapy Revenue, 2016-2021
4.2.2 By Type - United States Bi-Specific Antibodies Therapy Revenue, 2022-2027
4.2.3 By Type - United States Bi-Specific Antibodies Therapy Revenue Market Share, 2016-2027
5 Sights by Application
5.1 Overview
5.1.1 By Application - United States Bi-Specific Antibodies Therapy Market Size, 2021 & 2027
5.1.2 Cancer
5.1.3 Haemophilia
5.1.4 Other Non-Cancer Diseases
5.2 By Application - United States Bi-Specific Antibodies Therapy Revenue & Forecasts
5.2.1 By Application - United States Bi-Specific Antibodies Therapy Revenue, 2016-2021
5.2.2 By Application - United States Bi-Specific Antibodies Therapy Revenue, 2022-2027
5.2.3 By Application - United States Bi-Specific Antibodies Therapy Revenue Market Share, 2016-2027
6 Bi-Specific Antibodies Therapy Companies Profiles
6.1 Roche
6.1.1 Roche Company Details
6.1.2 Roche Business Overview
6.1.3 Roche Bi-Specific Antibodies Therapy Introduction
6.1.4 Roche Bi-Specific Antibodies Therapy Revenue in United States Market (2016-2021)
6.1.5 Roche Recent Developments
6.2 Amgen
6.2.1 Amgen Company Details
6.2.2 Amgen Business Overview
6.2.3 Amgen Bi-Specific Antibodies Therapy Introduction
6.2.4 Amgen Bi-Specific Antibodies Therapy Revenue in United States Market (2016-2021)
6.2.5 Amgen Recent Developments
6.3 Sanofi
6.3.1 Sanofi Company Details
6.3.2 Sanofi Business Overview
6.3.3 Sanofi Bi-Specific Antibodies Therapy Introduction
6.3.4 Sanofi Bi-Specific Antibodies Therapy Revenue in United States Market (2016-2021)
6.3.5 Sanofi Recent Developments
6.4 Pfizer
6.4.1 Pfizer Company Details
6.4.2 Pfizer Business Overview
6.4.3 Pfizer Bi-Specific Antibodies Therapy Introduction
6.4.4 Pfizer Bi-Specific Antibodies Therapy Revenue in United States Market (2016-2021)
6.4.5 Pfizer Recent Developments
6.5 Johnson & Johnson
6.5.1 Johnson & Johnson Company Details
6.5.2 Johnson & Johnson Business Overview
6.5.3 Johnson & Johnson Bi-Specific Antibodies Therapy Introduction
6.5.4 Johnson & Johnson Bi-Specific Antibodies Therapy Revenue in United States Market (2016-2021)
6.5.5 Johnson & Johnson Recent Developments
6.6 AstraZeneca
6.6.1 AstraZeneca Company Details
6.6.2 AstraZeneca Business Overview
6.6.3 AstraZeneca Bi-Specific Antibodies Therapy Introduction
6.6.4 AstraZeneca Bi-Specific Antibodies Therapy Revenue in United States Market (2016-2021)
6.6.5 AstraZeneca Recent Developments
6.7 AbbVie
6.7.1 AbbVie Company Details
6.7.2 AbbVie Business Overview
6.7.3 AbbVie Bi-Specific Antibodies Therapy Introduction
6.7.4 AbbVie Bi-Specific Antibodies Therapy Revenue in United States Market (2016-2021)
6.7.5 AbbVie Recent Developments
6.8 Lindis Biotech
6.8.1 Lindis Biotech Company Details
6.8.2 Lindis Biotech Business Overview
6.8.3 Lindis Biotech Bi-Specific Antibodies Therapy Introduction
6.8.4 Lindis Biotech Bi-Specific Antibodies Therapy Revenue in United States Market (2016-2021)
6.8.5 Lindis Biotech Recent Developments
6.9 MacroGenics, Inc
6.9.1 MacroGenics, Inc Company Details
6.9.2 MacroGenics, Inc Business Overview
6.9.3 MacroGenics, Inc Bi-Specific Antibodies Therapy Introduction
6.9.4 MacroGenics, Inc Bi-Specific Antibodies Therapy Revenue in United States Market (2016-2021)
6.9.5 MacroGenics, Inc Recent Developments
6.10 Genmab
6.10.1 Genmab Company Details
6.10.2 Genmab Business Overview
6.10.3 Genmab Bi-Specific Antibodies Therapy Introduction
6.10.4 Genmab Bi-Specific Antibodies Therapy Revenue in United States Market (2016-2021)
6.10.5 Genmab Recent Developments
6.11 Alphamab Co. Ltd
6.11.1 Alphamab Co. Ltd Company Details
6.11.2 Alphamab Co. Ltd Business Overview
6.11.3 Alphamab Co. Ltd Bi-Specific Antibodies Therapy Introduction
6.11.4 Alphamab Co. Ltd Bi-Specific Antibodies Therapy Revenue in United States Market (2016-2021)
6.11.5 Alphamab Co. Ltd Recent Developments
6.12 Akeso, Inc.
6.12.1 Akeso, Inc. Company Details
6.12.2 Akeso, Inc. Business Overview
6.12.3 Akeso, Inc. Bi-Specific Antibodies Therapy Introduction
6.12.4 Akeso, Inc. Bi-Specific Antibodies Therapy Revenue in United States Market (2016-2021)
6.12.5 Akeso, Inc. Recent Developments
7 Conclusion
8 Appendix
8.1 Note
8.2 Examples of Clients
8.3 Author Details
8.4 Disclaimer
List of TablesTable 1. Bi-Specific Antibodies Therapy Market Opportunities & Trends in United States Market
Table 2. Bi-Specific Antibodies Therapy Market Drivers in United States Market
Table 3. Bi-Specific Antibodies Therapy Market Restraints in United States Market
Table 4. Key Players of Bi-Specific Antibodies Therapy in United States Market
Table 5. Top Bi-Specific Antibodies Therapy Players in United States Market, Ranking by Revenue (2019)
Table 6. United States Bi-Specific Antibodies Therapy Revenue by Companies, (US$, Mn), 2016-2021
Table 7. United States Bi-Specific Antibodies Therapy Revenue Share by Companies, 2016-2021
Table 8. Companies Bi-Specific Antibodies Therapy Product Type
Table 9. List of Tier 1 Bi-Specific Antibodies Therapy Companies, Revenue (US$, Mn) in 2020 and Market Share
Table 10. List of Tier 2 and Tier 3 Bi-Specific Antibodies Therapy Companies, Revenue (US$, Mn) in 2020 and Market Share
Table 11. By Type - United States Bi-Specific Antibodies Therapy Revenue, (US$, Mn), 2021 & 2027
Table 12. By Type - United States Bi-Specific Antibodies Therapy Revenue (US$, Mn), 2016-2021
Table 13. By Type - United States Bi-Specific Antibodies Therapy Revenue (US$, Mn), 2022-2027
Table 14. By Application - United States Bi-Specific Antibodies Therapy Revenue, (US$, Mn), 2021 VS 2027
Table 15. By Application - United States Bi-Specific Antibodies Therapy Revenue (US$, Mn), 2016-2021
Table 16. By Application - United States Bi-Specific Antibodies Therapy Revenue (US$, Mn), 2022-2027
Table 17. Roche Company Details
Table 18. Roche Business Overview
Table 19. Roche Bi-Specific Antibodies Therapy Product
Table 20. Roche Bi-Specific Antibodies Therapy Revenue in United States Market (2016-2021) & (US$ Million)
Table 21. Roche Recent Developments
Table 22. Amgen Company Details
Table 23. Amgen Business Overview
Table 24. Amgen Bi-Specific Antibodies Therapy Product
Table 25. Amgen Bi-Specific Antibodies Therapy Revenue in United States Market (2016-2021) & (US$ Million)
Table 26. Amgen Recent Developments
Table 27. Sanofi Company Details
Table 28. Sanofi Business Overview
Table 29. Sanofi Bi-Specific Antibodies Therapy Product
Table 30. Sanofi Bi-Specific Antibodies Therapy Revenue in United States Market (2016-2021) & (US$ Million)
Table 31. Sanofi Recent Developments
Table 32. Pfizer Company Details
Table 33. Pfizer Business Overview
Table 34. Pfizer Bi-Specific Antibodies Therapy Product
Table 35. Pfizer Bi-Specific Antibodies Therapy Revenue in United States Market (2016-2021) & (US$ Million)
Table 36. Pfizer Recent Developments
Table 37. Johnson & Johnson Company Details
Table 38. Johnson & Johnson Business Overview
Table 39. Johnson & Johnson Bi-Specific Antibodies Therapy Product
Table 40. Johnson & Johnson Bi-Specific Antibodies Therapy Revenue in United States Market (2016-2021) & (US$ Million)
Table 41. Johnson & Johnson Recent Developments
Table 42. AstraZeneca Company Details
Table 43. AstraZeneca Business Overview
Table 44. AstraZeneca Bi-Specific Antibodies Therapy Product
Table 45. AstraZeneca Bi-Specific Antibodies Therapy Revenue in United States Market (2016-2021) & (US$ Million)
Table 46. AstraZeneca Recent Developments
Table 47. AbbVie Company Details
Table 48. AbbVie Business Overview
Table 49. AbbVie Bi-Specific Antibodies Therapy Product
Table 50. AbbVie Bi-Specific Antibodies Therapy Revenue in United States Market (2016-2021) & (US$ Million)
Table 51. AbbVie Recent Developments
Table 52. Lindis Biotech Company Details
Table 53. Lindis Biotech Business Overview
Table 54. Lindis Biotech Bi-Specific Antibodies Therapy Product
Table 55. Lindis Biotech Bi-Specific Antibodies Therapy Revenue in United States Market (2016-2021) & (US$ Million)
Table 56. Lindis Biotech Recent Developments
Table 57. MacroGenics, Inc Company Details
Table 58. MacroGenics, Inc Business Overview
Table 59. MacroGenics, Inc Bi-Specific Antibodies Therapy Product
Table 60. MacroGenics, Inc Bi-Specific Antibodies Therapy Revenue in United States Market (2016-2021) & (US$ Million)
Table 61. MacroGenics, Inc Recent Developments
Table 62. Genmab Company Details
Table 63. Genmab Business Overview
Table 64. Genmab Bi-Specific Antibodies Therapy Product
Table 65. Genmab Bi-Specific Antibodies Therapy Revenue in United States Market (2016-2021) & (US$ Million)
Table 66. Genmab Recent Developments
Table 67. Alphamab Co. Ltd Company Details
Table 68. Alphamab Co. Ltd Business Overview
Table 69. Alphamab Co. Ltd Bi-Specific Antibodies Therapy Product
Table 70. Alphamab Co. Ltd Bi-Specific Antibodies Therapy Revenue in United States Market (2016-2021) & (US$ Million)
Table 71. Alphamab Co. Ltd Recent Developments
Table 72. Akeso, Inc. Company Details
Table 73. Akeso, Inc. Business Overview
Table 74. Akeso, Inc. Bi-Specific Antibodies Therapy Product
Table 75. Akeso, Inc. Bi-Specific Antibodies Therapy Revenue in United States Market (2016-2021) & (US$ Million)
Table 76. Akeso, Inc. Recent Developments
List of FiguresFigure 1. Bi-Specific Antibodies Therapy Segment by Type
Figure 2. Bi-Specific Antibodies Therapy Segment by Application
Figure 3. United States Bi-Specific Antibodies Therapy Market Overview: 2020
Figure 4. United States Bi-Specific Antibodies Therapy Market Size: 2021 VS 2027 (US$, Mn)
Figure 5. United States Bi-Specific Antibodies Therapy Revenue, 2016-2027 (US$, Mn)
Figure 6. The Top 3 and 5 Players Market Share by Bi-Specific Antibodies Therapy Revenue in 2020
Figure 7. By Type - United States Bi-Specific Antibodies Therapy Revenue Market Share, 2016-2027
Figure 8. By Application - United States Bi-Specific Antibodies Therapy Revenue Market Share, 2016-2027
Figure 9. Roche Bi-Specific Antibodies Therapy Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 10. Amgen Bi-Specific Antibodies Therapy Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 11. Sanofi Bi-Specific Antibodies Therapy Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 12. Pfizer Bi-Specific Antibodies Therapy Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 13. Johnson & Johnson Bi-Specific Antibodies Therapy Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 14. AstraZeneca Bi-Specific Antibodies Therapy Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 15. AbbVie Bi-Specific Antibodies Therapy Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 16. Lindis Biotech Bi-Specific Antibodies Therapy Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 17. MacroGenics, Inc Bi-Specific Antibodies Therapy Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 18. Genmab Bi-Specific Antibodies Therapy Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 19. Alphamab Co. Ltd Bi-Specific Antibodies Therapy Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 20. Akeso, Inc. Bi-Specific Antibodies Therapy Revenue Year Over Year Growth (US$, Mn) & (2016-2021)